We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Amgen Denied Full Fed. Circ. Hearing On Repatha Patents

Law360 (February 23, 2018, 8:42 PM EST) -- The full Federal Circuit will not review a panel decision that revived a challenge to Amgen’s patents for Repatha, an antibody-based cholesterol treatment, according to a decision issued by the appeals court Friday.

In a per curiam decision, the appeals court’s 12 active judges denied Amgen Inc.’s petition for a panel rehearing or rehearing en banc, more than two months after the drugmaker had argued that in nullifying its patent win over Sanofi and Regeneron Pharmaceuticals Inc., a three-judge panel abandoned precedent by rejecting a previously...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.